Biopas and moksha8 Announce Strategic Alliance to Commercialize Specialty Pharmaceuticals Across Latin America - WOWK 13 Charleston, Huntington WV News, Weather, Sports

Biopas and moksha8 Announce Strategic Alliance to Commercialize Specialty Pharmaceuticals Across Latin America

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE moksha8

SAO PAULO and PANAMA CITY, June 16, 2014 /PRNewswire/ -- Biopas and moksha8, two leading specialty pharmaceutical companies, announced today that they have entered into a strategic alliance combining strong capabilities, regional presence and product pipelines.  The alliance immediately creates a unique regional provider of high quality, specialty pharmaceutical products across one of the world's fastest growing, high value markets.  Biopas and moksha8 will collaborate on both existing and future corporate development partnerships. 

The Latin America retail pharmaceutical market is estimated by IMS at USD $68 billion in 2013, growing at 12% CAGR to over USD $110 billion by 2017.  Brazil is expected to be the fourth largest pharmaceutical market in the world by 2017. 

The alliance provides a high quality, FCPA compliant one-stop shop to obtain regulatory approval and commercialize specialty pharmaceutical products throughout the Latin American region. 

Both Biopas and moksha8 have strong existing partnerships with exclusive rights to high value products from companies including UCB, Ferring, Forest Laboratories, GSK, Sandoz and Ipsen.  Among key brands are Viibryd, Cimzia, Dysport, Utrogestan, Queopine and Razapina.  moksha8 has operations in Brazil and Mexico and Biopas has operations in the other key Latin America markets including Colombia, Venezuela, Argentina and Central America. 

Biopas and moksha8 will initiate the alliance through commercialization of Viibryd (vilazodone HCL) as a regional, Latin America brand.  Viibryd is the first and only selective serotonin reuptake inhibitor  and 5HT1A receptor partial agonist antidepressant to receive approval from the FDA. 

Simba Gill, CEO of moksha8 and Pascal Forget, CEO of Biopas highlighted that "both companies share a common set of values and culture, which form a strong foundation to realize the full value of our products in Latin America and provide significant competitive advantages and differentiation".

About moksha8
moksha8 is a leading Latin American pharmaceutical company, with a core focus on commercializing the highest quality medicines with best in class operations and strong FCPA compliance.  The company launched its commercial operations in 2008 in Brazil and Mexico promoting primarily CNS products.  moksha8 has a broad alliance with Forest Laboratories throughout Latin America and partnerships with GSK, Sandoz, Aurobindo and Accord in Brazil.  The company was founded by Simba Gill and TPG Biotechnology.  Major investors include TPG Biotechnology and Montreux Equity Partners.  For additional information on moksha8, please visit the company's web site at www.moksha8.com.

About Biopas
Established in 2002, Biopas is a leading Latin American pharmaceutical company with a particular focus on carving out strong market positions for exclusive products towards unmet critical patients' needs.    Biopas' outstanding market access strategy and strict compliance policies allowed it to build long-standing commercial relationships with multiple leading international companies.   Biopas operates in most of Latin America and commercializes a unique portfolio of lead products including CNS, cardiology, rheumatology, women's health, gastroenterology and dermo-cosmetics products. Since 2002, Biopas achieved steady and outstanding annual revenue growth and products' portfolio expansion.  For additional information on Biopas, please visit the company's web site at www.biopasgroup.com

©2012 PR Newswire. All Rights Reserved.